Abstract: The designers' tendency to adhere to a specific mental set and heavy emotional investment in their initial ideas often limit their ability to innovate during the design ideation process. The ...
Abstract: Pedestrian attribute recognition (PAR), which aims to identify attributes of the pedestrians captured in video surveillance, is a challenging task due to the poor quality of images and ...
With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the ...
Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.
Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies. This episode, titled ‘Navigating Benefit Design and Utilization ...
AI technology and cardiac MRI scans were used to create ECV maps of more than 60 patients with ATTR-CM from an international clinical trial. Among the patients in a study, the distribution of ...
Good morning, everyone, and thank you for joining us today. I'm Tolga Tanguler, Chief Commercial Officer at Alnylam, and I'm thrilled to be hosting today's webinar to update you on our leadership ...
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing. All the news that moves the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results